Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

2,075.00p
   
  • Change Today:
    -25.00p
  • 52 Week High: 3,775.00p
  • 52 Week Low: 1,835.00p
  • Currency: UK Pounds
  • Shares Issued: 5.22m
  • Volume: 2,113
  • Market Cap: £108.42m

Bioventix share price spikes after trading update

By Iain Gilbert

Date: Monday 04 Sep 2017

LONDON (ShareCast) - (ShareCast News) - Clinical antibody specialist Bioventix expects revenues and pre-tax profits to be ahead of market projections for the year after its revenue increased by almost a quarter.
Bioventix, which specialises in the development and commercial supply of high-affinity monoclonal antibodies for clinical diagnostics, said revenue would top £7m for the year, up 24% from the £5.5m the previous year.

Profits would also be boosted thanks to a "similar shallow trajectory" for its cost base that the group had reported in previous years.

The firm said its full audited accounts would be released on 17 October, ahead of its annual general meeting on 14 December.

As of 0910 BST, shares had gained 11.39% to 2,445.00p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 2,075.00p
Change Today -25.00p
% Change -1.19 %
52 Week High 3,775.00p
52 Week Low 1,835.00p
Volume 2,113
Shares Issued 5.22m
Market Cap £108.42m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
23.47% above the market average23.47% above the market average23.47% above the market average23.47% above the market average23.47% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
67.33% below the market average67.33% below the market average67.33% below the market average67.33% below the market average67.33% below the market average
31.82% below the sector average31.82% below the sector average31.82% below the sector average31.82% below the sector average31.82% below the sector average
Income
60.89% above the market average60.89% above the market average60.89% above the market average60.89% above the market average60.89% above the market average
33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average33.33% above the sector average
Growth
5.71% below the market average5.71% below the market average5.71% below the market average5.71% below the market average5.71% below the market average
65.52% below the sector average65.52% below the sector average65.52% below the sector average65.52% below the sector average65.52% below the sector average

Bioventix Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 06-Nov-25 10-Apr-25
Paid 21-Nov-25 25-Apr-25
Amount 80.00p 70.00p

Trades for 20-Nov-2025

Time Volume / Share Price
16:04 38 @ 2,091.00p
15:50 47 @ 2,091.00p
15:49 181 @ 2,050.00p
15:24 256 @ 2,092.00p
14:33 181 @ 2,075.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page